SABCOMELINE

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C10H15N3O
Molecular Weight	193.2456
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

SMILES

CO\N=C(/C#N)[C@H]1CN2CCC1CC2

InChI

InChIKey=IQWCBYSUUOFOMF-QTLFRQQHSA-N

InChI=1S/C10H15N3O/c1-14-12-10(6-11)9-7-13-4-2-8(9)3-5-13/h8-9H,2-5,7H2,1H3/b12-10+/t9-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C10H15N3O
Molecular Weight	193.2456
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	1
Optical Activity	UNSPECIFIED

Description

Sabcomeline (SB-202026) is a potent and functionally selective M1 receptor partial agonist that originally was developed by GlaxoSmithKline. Sabcomeline had been in phase III clinical trials for the treatment of Alzheimer's disease and phase II for schizophrenia and major depressive disorder. In addition, it was studied for patients with Type 2 diabetes mellitus. However, due to poor results, the development of this drug was discontinued.

Originator

Approval Year

PubMed

PubMed

Show entries

Title	Date	PubMed
SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors.	1997 Dec	9399977
Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.	1997 Dec 19	9435896
Sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, reverses delay-induced deficits in the T-maze.	1998 Aug	9725749
The profile of sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, in the marmoset.	1998 May	9641560
Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline.	2001 Mar	11181912